

The Crutchfield-Kannan JAK Inhibitors Pending FDA Approval

Indication	Brand Name	Generic Name	Ages (years)	Oral or Topical	Manufacturer	Clinical Phase	JAK1	JAK2	JAK3	TYK2	SYK
Alopecia Areata	Sotyktu	deucravacitinib	≥18	oral	Bristol Myers Squibb	Phase II				x	
	CTP-543	deuruxolitinib		oral	Concert Pharmaceuticals	Phase III	x	x			
	PF-06651600	rittlecitinib	≥12	oral	Pfizer	Preregistration			x		
	Jakafi	ruxolitinib		oral	Incyte Corp	Phase II	x	x		2°	
	Xeljanz	tofacitinib	≥18	oral	Pfizer	Phase IV	x	2°	x		
Atopic Dermatitis	Olumiant	baricitinib	≥18	oral	Eli Lilly; Incyte	Phase III	x	x		x	
	Corectim	delgocitinib		topical	Leo Pharma	Phase III, Fast Track Designation	x	x	x	x	
	ASN002	gusacitinib		oral	Asana Biosciences	Phase II	x	x	x	x	x
	Xeljanz	tofacitinib	≥18	topical	Pfizer	Phase II	x	2°	x		
Chronic Hand Eczema	Corectim	delgocitinib		topical	Leo Pharma	Phase III, Fast Track Designation	x	x	x	x	
	ASN002	gusacitinib	≥18	oral	Asana Biosciences	Phase II, Fast Track Designation	x	x	x	x	x
	Opzelura	ruxolitinib		topical	Incyte Corp	Phase III	x	x		2°	
Crohn's Disease	PF-06651600	rittlecitinib		oral	Pfizer	Phase II			x		
Cutaneous Lupus Erythematosus	Sotyktu	deucravacitinib		oral	Bristol Myers Squibb	Phase II				x	
	Jyseleca	filgotinib		oral	Galapagos; Gilead Sciences	Phase II	x				
	GS 9876	lanraplenib		oral	Gilead Sciences; Kronos Bio	Phase II					x
Dermatomyositis	PF-06700841	brepocitinib		oral	Pfizer; Priovant	Phase III	x			x	
	Xeljanz	tofacitinib	≥18	oral	Pfizer	Phase I	x	2°	x		
Discoid Lupus Erythematosus	Sotyktu	deucravacitinib		oral	Bristol Myers Squibb	Phase II				x	
	Jakafi	ruxolitinib		oral	Incyte Corp	Phase II	x	x		2°	
Erythrodermic psoriasis	Sotyktu	deucravacitinib		oral	Bristol Myers Squibb	Preregistration				x	
Graft-versus-host disease	Olumiant	baricitinib	≥18	oral	Eli Lilly; Incyte	Phase II	x	x		x	
	IBI-377	itacitinib		oral	Incyte Corp	Phase III	x	x			
Hidradenitis Suppurativa	PF-06700841	brepocitinib		oral	Pfizer; Priovant	Phase II	x			x	
	INCB54707	povorcitinib		oral	Incyte Corp	Phase II	x				
	Jakafi	ruxolitinib		oral	Incyte Corp	Phase II	x	x		2°	
Prurigo Nodularis	Cibinqo	abrocitinib		oral	Pfizer	Phase II	x	2°		2°	
	INCB54707	povorcitinib		oral	Incyte Corp	Phase II	x				
Pruritus	Cibinqo	abrocitinib		oral	Pfizer	Phase II	x	2°		2°	
Psoriasis	Sotyktu	deucravacitinib		oral	Bristol Myers Squibb	Phase III				x	
	Opzelura	ruxolitinib		topical	Incyte Corp	Phase II	x	x		2°	
	Xeljanz	tofacitinib	≥18	oral	Pfizer	Phase III	x	2°	x		
Psoriatic Arthritis	Sotyktu	deucravacitinib	≥18	oral	Bristol Myers Squibb	Phase III				x	
Rheumatoid Arthritis	Jyseleca	filgotinib	≥18	oral	Galapagos; Gilead Sciences	^{g,h}	x				
	GS 9876	lanraplenib		oral	Gilead Sciences; Kronos Bio	Phase II					x
	PF-06651600	rittlecitinib		oral	Pfizer	Phase II			x		
Sjögren's Syndrome	GS 9876	lanraplenib		oral	Gilead Sciences; Kronos Bio	Phase II					x
Systemic Lupus Erythematosus	Olumiant	baricitinib	≥18	oral	Eli Lilly; Incyte Corp.	Phase III	x	x		x	
	PF-06700841	brepocitinib		oral	Pfizer; Priovant	Phase II	x			x	
	Sotyktu	deucravacitinib		oral	Bristol Myers Squibb	Phase II				x	
Ulcerative Colitis	PF-06651600	rittlecitinib		oral	Pfizer	Phase III			x		
Vitiligo	INCB54707	povorcitinib		oral	Incyte Corp	Phase II	x				
	PF-06651600	rittlecitinib		oral	Pfizer	Phase II			x		

^g Not pursuing FDA approval. Only approved in Japan and Europe.

Dosing: 200 mg qd; can lower to 100 mg qd

